Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
GlaxoSmithKline plc (GSK) is a leading drug manufacturers-general business based in the US. It opened the day at USD$45.31 after a previous close of USD$45.06. During the day the price has varied from a low of USD$45.22 to a high of USD$45.6689. The latest price was USD$45.47 (25 minute delay). GlaxoSmithKline is listed on the NYSE and employs 90,096 staff. All prices are listed in US Dollars.
| Open | $45.31 |
|---|---|
| High | $45.67 |
| Low | $45.22 |
| Close | $45.47 |
| Previous close | $45.06 |
| Change | $0.41 |
| Change % | 0.9099% |
| Volume | 3,395,971 |
| 52-week range | $36.43 - $46.59 |
|---|---|
| 50-day moving average | $44.23 |
| 200-day moving average | $42.50 |
| Wall St. target price | $49.81 |
| PE ratio | 17.8452 |
| Dividend yield | $0.75 (4.46%) |
| Earnings per share (TTM) | $2.52 |
Historical closes compared with the close of $45.47 from 2022-05-24
| 1 week (2022-05-18) | 4.22% |
|---|---|
| 1 month (2022-04-26) | 2.43% |
| 3 months (2022-02-25) | 6.54% |
| 6 months (2021-11-26) | 10.85% |
| 1 year (2021-05-26) | 17.46% |
|---|---|
| 2 years (2020-05-26) | 11.58% |
| 3 years (2019-05-24) | 13.17% |
| 5 years (2017-05-25) | 6.81% |
Valuing GlaxoSmithKline stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of GlaxoSmithKline's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
GlaxoSmithKline's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 18x. In other words, GlaxoSmithKline shares trade at around 18x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
GlaxoSmithKline's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.9095. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into GlaxoSmithKline's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
GlaxoSmithKline's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $10.8 billion.
The EBITDA is a measure of a GlaxoSmithKline's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $36.5 billion |
|---|---|
| Operating margin TTM | 23.4% |
| Gross profit TTM | $22.7 billion |
| Return on assets TTM | 6.36% |
| Return on equity TTM | 27.51% |
| Profit margin | 14.02% |
| Book value | $6.43 |
| Market capitalisation | $114.3 billion |
TTM: trailing 12 months
Dividend payout ratio: 59.9% of net profits
Recently GlaxoSmithKline has paid out, on average, around 59.9% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 4.46% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), GlaxoSmithKline shareholders could enjoy a 4.46% return on their shares, in the form of dividend payments. In GlaxoSmithKline's case, that would currently equate to about $0.75 per share.
GlaxoSmithKline's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
GlaxoSmithKline's most recent dividend payout was on 30 June 2022. The latest dividend was paid out to all shareholders who bought their shares by 18 May 2022 (the "ex-dividend date").
GlaxoSmithKline's shares were split on a 2:1 basis on 11 November 1991. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your GlaxoSmithKline shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for GlaxoSmithKline shares which in turn could have impacted GlaxoSmithKline's share price.
Over the last 12 months, GlaxoSmithKline's shares have ranged in value from as little as $36.4262 up to $46.5936. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while GlaxoSmithKline's is 0.2895. This would suggest that GlaxoSmithKline's shares are less volatile than average (for this exchange).
GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc. ; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.
Your detailed review of share trading with BlackBull Markets, including brokerage fees, safety, pros and cons, and more.
Thinking of trading shares with Jarden Direct? Check out our review of Jarden Direct fees, safety, and pros and cons first.
Your detailed review of online share trading with Tiger Brokers, including fees, markets, safety, pros and cons, and how to sign up.
A growing number of Kiwis are investing in the stock market via an app or online platform, according to research by Finder.
The second Bitcoin future ETF is set to go live Oct. 22. Here’s how to invest if you’re in New Zealand.
Steps to owning and managing VanEck Bitcoin Strategy ETF units.
Steps to owning and managing ProShares Bitcoin Strategy ETF, with 24-hour and historical pricing before you buy.
We present the 10 best performing shares on the NZX over the last 3 months and show you how you can invest in them.
Fractional shares are fractions of company shares. Sometimes they’re made by brokers to allow those with limited funds to get access to stocks.
How day trading works, what to watch out for and how to pick a broker.